Page last updated: 2024-12-07

a 82846a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	122131
CHEMBL ID	411769
MeSH ID	M0152173

Synonyms (8)

Synonym
110865-90-2
eremomycin
a 82846a
CHEMBL411769
a82846a
8-82846b
AKOS015969708
gtpl10959

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" LD50 of eremomycin on its intravenous administration to albino mice amounted to 1760 (1460-2130) mg/kg."	( [Preclinical toxicological study of the new antibiotic eremomycin. Its acute toxicity for laboratory animals]. Gol'dberg, LE; Shepelevtseva, NG; Shevniuk, LA; Stepanova, ES; Vertogradova, TP, 1987)	0.27

Compound-Compound Interactions

Excerpt	Reference	Relevance
" Activity of eremomycin alone or in combination with tobramycin was studied with using 25 clinical strains of staphylococci."	( [Study of the activity of a new glycopeptide antibiotic eremomycin combined with tobramycin against Staphylococci in vitro]. Iakushkina, IV; Malkova, IV; Prozorova, IN, 1988)	0.27

Bioavailability

Excerpt	Reference	Relevance
" Bioavailability of eremomycin and teichoplanin after their extravascular administration was the same and amounted to 94 per cent."	( [Glycopeptide antibiotics: eremomycin, vancomycin, and teicoplanin. Comparison of several parameters of pharmacokinetics and antimicrobial activity]. Filippos'iants, ST; Gol'dberg, LE; Malkova, IV, 1989)	0.28
" Absolute bioavailability after subcutaneous administration averaged to 85 per cent."	( [Pharmacokinetic study of eremomycin in an experiment]. Filippos'iants, ST; Malkova, IV, 1987)	0.27

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay ID	Title	Year	Journal	Article
AID44140	Minimal inhibitory concentration required to cause a microscopic detectable alteration of C3H/3T3 embryo murine fibroblast cell morphology	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
AID105655	Inhibitory concentration of compound against proliferation of human T-lymphocytic cells MOLT-4/C8 was determined	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
AID206213	Antibacterial activity against Staphylococcus epidermis 533 strain	2003	Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7	Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID82110	Effective concentration of compound required to protect human T-lymphocytic cells against the cytopathogenicity of HIV-1	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
AID207011	Antibacterial activity against glycopeptide intermediate resistant Staphylococcus aureus 3798 strain	2003	Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7	Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID207010	Antibacterial activity against glycopeptide intermediate resistant Staphylococcus aureus 3797 strain	2003	Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7	Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID68068	Antibacterial activity against glycopeptide resistant Enterococcus faecium 569 strain	2003	Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7	Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID47433	Inhibitory concentration against proliferation of human T-lymphocytic (CEM) cells	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
AID66902	Antibacterial activity against glycopeptide resistant Enterococcus faecalis 560 strain	2003	Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7	Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID98356	Inhibitory concentration of compound against proliferation of murine lukemia cells L1210 was determined	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
AID209587	Antibacterial activity against Streptococcus haemolyticus 602 strain	2003	Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7	Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID66903	Antibacterial activity against glycopeptide susceptible Enterococcus faecalis 559 strain	2003	Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7	Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID106723	Effective concentration of compound required to protect C3H/3T3 embryo murine fibroblasts against the MSV induced transformation	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
AID83111	Concentration required to protect human T-lymphocytic cells against the cytopathogenicity of HIV-2	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics.
AID68069	Antibacterial activity against glycopeptide susceptible Enterococcus faecium 568 strain	2003	Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7	Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (73)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	17 (23.29)	18.7374
1990's	20 (27.40)	18.2507
2000's	27 (36.99)	29.6817
2010's	8 (10.96)	24.3611
2020's	1 (1.37)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	10.06 (24.57)
Research Supply Index	4.38 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (10.06)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (1.27%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	78 (98.73%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
acetaldehyde Acetaldehyde: A colorless, flammable liquid used in the manufacture of acetic acid, perfumes, and flavors. It is also an intermediate in the metabolism of alcohol. It has a general narcotic action and also causes irritation of mucous membranes. Large doses may cause death from respiratory paralysis.. acetaldehyde : The aldehyde formed from acetic acid by reduction of the carboxy group. It is the most abundant carcinogen in tobacco smoke.. aldehyde : A compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.. acetyl group : A group, formally derived from acetic acid by dehydroxylation, which is fundamental to the biochemistry of all forms of life. When bound to coenzyme A, it is central to the metabolism of carbohydrates and fats.	2	1	aldehyde	carcinogenic agent; EC 3.5.1.4 (amidase) inhibitor; electron acceptor; Escherichia coli metabolite; human metabolite; mouse metabolite; mutagen; oxidising agent; Saccharomyces cerevisiae metabolite; teratogenic agent
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	2	1	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glycine [no description available]	2.03	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	2.1	1	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
flurbiprofen Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.	2.05	1	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
alanine Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.	2.74	3	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite
methicillin Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.	2	1	penicillin allergen; penicillin	antibacterial drug
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.03	1	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
asparagine Asparagine: A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed). asparagine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 2-amino-2-oxoethyl group.	2	1	amino acid zwitterion; asparagine; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
acetonitrile acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.	2.1	1	aliphatic nitrile; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; NMR chemical shift reference compound; polar aprotic solvent
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	5.9	32	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
hexadimethrine bromide Hexadimethrine Bromide: A synthetic polymer which agglutinates red blood cells. It is used as a heparin antagonist.	2.01	1
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	1.99	1	pseudohalide anion	mitochondrial respiratory-chain inhibitor
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	2.38	2	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	2.73	3
eremomycin aglycone [no description available]	2.9	4
chloroorienticin b chloroorienticin B: structure given in first source; isolated from Amycolatopsis orientalis. chloroorienticin B : A glycopeptide that is isolated from Amycolatopsis orientalis.	1.97	1	cyclic ether; glycopeptide; heterodetic cyclic peptide; monosaccharide derivative; organochlorine compound; polyphenol	antimicrobial agent; bacterial metabolite
glycosides [no description available]	2.37	2
lincomycin Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.	2.38	2	carbohydrate-containing antibiotic; L-proline derivative; monocarboxylic acid amide; pyrrolidinecarboxamide; S-glycosyl compound	antimicrobial agent; bacterial metabolite
avoparcin avoparcin: glycopeptide antibiotic from Streptomyces candidus; antibiotic growth promoter for improving growth rates & feed conversion efficiency of broiler chickens & pigs	2	1
teicoplanin aglycone [no description available]	2.01	1	oligopeptide
ristocetin Ristocetin: An antibiotic mixture of two components, A and B, obtained from Nocardia lurida (or the same substance produced by any other means). It is no longer used clinically because of its toxicity. It causes platelet agglutination and blood coagulation and is used to assay those functions in vitro.. ristocetin : A heterodetic cyclic peptide that is produced by species of Amycolatopsis and Nocardia.	4.69	9	glycopeptide; heterodetic cyclic peptide; macrocycle; tetrasaccharide derivative	antibacterial drug; antimicrobial agent; bacterial metabolite; platelet-activating factor receptor agonist
tylosin [no description available]	2.08	1
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.06	1	benzenes; hydroxycoumarin; methyl ketone
agar Agar: A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis.. agar : A complex mixture of polysaccharides extracted from species of red algae. Its two main components are agarose and agaropectin. Agarose is the component responsible for the high-strength gelling properties of agar, while agaropectin provides the viscous properties.	1.97	1
chloroeremomycin chloroeremomycin: structure given in first source. chloroeremomycin : A complex glycopeptide antibiotic that is isolated from Amycolatopsis orientalis.. chloroeremomycin(2+) : An organic cation obtained by deprotonation of the carboxy group and protonation of the three amino functions of chloroeremomycin; major species at pH 7.3.	2.7	3	organic cation
chloroorienticin a chloroorienticin A: structure given in first source; isolated from Amycolatopsis orientalis	3.48	2
a 40926 A 40926: from Actinomadura; active against gram-positive bacteria & Neisseria gonorrhoeae	3.09	1
teicoplanin aglycone teicoplanin aglycone: structure given in first source	2.44	2

Condition	Relationship Strength	Studies
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	2.17	1
Electrolytes Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)	2.05	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.74	3
Infections, Staphylococcal [description not available]	2.89	4
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	2.89	4
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.38	2
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	1.98	1
Antibiotic-Associated Colitis [description not available]	1.98	1
Enterocolitis, Pseudomembranous An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.	1.98	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	1.97	1
Allergy, Drug [description not available]	1.97	1
Anasarca [description not available]	1.97	1
Hematochezia The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.	1.97	1
Active Hyperemia [description not available]	1.97	1
Atopic Hypersensitivity [description not available]	1.97	1
Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.	1.97	1
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	1.97	1
Gastrointestinal Hemorrhage Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.	1.97	1
Hyperemia The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).	1.97	1
Group A Strep Infection [description not available]	2.38	2
Streptococcal Infections Infections with bacteria of the genus STREPTOCOCCUS.	2.38	2

chemdatabank.com